WO2008078715A1 - Agent thérapeutique pour une myopathie inflammatoire contenant un antagoniste de il-6 en tant qu'ingrédient actif - Google Patents

Agent thérapeutique pour une myopathie inflammatoire contenant un antagoniste de il-6 en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2008078715A1
WO2008078715A1 PCT/JP2007/074751 JP2007074751W WO2008078715A1 WO 2008078715 A1 WO2008078715 A1 WO 2008078715A1 JP 2007074751 W JP2007074751 W JP 2007074751W WO 2008078715 A1 WO2008078715 A1 WO 2008078715A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
inflammatory myopathy
antagonist
active ingredient
inflammatory
Prior art date
Application number
PCT/JP2007/074751
Other languages
English (en)
Japanese (ja)
Inventor
Hitoshi Kohsaka
Nobuyuki Miyasaka
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
National University Corporation Tokyo Medical And Dental University
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39562504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008078715(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha, National University Corporation Tokyo Medical And Dental University, Riken filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of WO2008078715A1 publication Critical patent/WO2008078715A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un excellent agent thérapeutique pour une myopathie inflammatoire qui peut supprimer de façon significative les symptômes d'une myopathie inflammatoire, tels qu'une infiltration cellulaire inflammatoire anormale dans les fibres musculaires, et qui n'a pas les inconvénients des médicaments classiques, tels qu'une diminution générale de l'immunocompétence. Autrement dit, l'invention concerne un agent thérapeutique pour une myopathie inflammatoire, caractérisé par le fait qu'il contient un antagoniste de IL-6 en tant qu'ingrédient actif. Dans l'agent thérapeutique pour une myopathie inflammatoire, l'antagoniste de IL-6 est, de préférence, un anticorps dirigé contre un récepteur de IL-6, un anticorps monoclonal ou similaire.
PCT/JP2007/074751 2006-12-27 2007-12-21 Agent thérapeutique pour une myopathie inflammatoire contenant un antagoniste de il-6 en tant qu'ingrédient actif WO2008078715A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006351695A JP2010095445A (ja) 2006-12-27 2006-12-27 Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
JP2006-351695 2006-12-27

Publications (1)

Publication Number Publication Date
WO2008078715A1 true WO2008078715A1 (fr) 2008-07-03

Family

ID=39562504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074751 WO2008078715A1 (fr) 2006-12-27 2007-12-21 Agent thérapeutique pour une myopathie inflammatoire contenant un antagoniste de il-6 en tant qu'ingrédient actif

Country Status (5)

Country Link
JP (1) JP2010095445A (fr)
AR (1) AR064538A1 (fr)
CL (1) CL2007003817A1 (fr)
PE (1) PE20081547A1 (fr)
WO (1) WO2008078715A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US8568720B2 (en) 2007-12-27 2013-10-29 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US8580264B2 (en) 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
US8709409B2 (en) 2003-04-28 2014-04-29 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US9017677B2 (en) 1997-03-21 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Methods of treating a disease mediated by sensitized T cells
US9255145B2 (en) 2001-04-02 2016-02-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US10168326B2 (en) 2013-07-04 2019-01-01 F. Hoffmann-La Roche Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US10501769B2 (en) 2009-10-26 2019-12-10 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899902A (ja) * 1994-09-30 1996-04-16 Chugai Pharmaceut Co Ltd Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
JPH08208514A (ja) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分とする慢性関節リウマチ治療剤
JPH10324639A (ja) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
WO1999047170A1 (fr) * 1998-03-17 1999-09-23 Chugai Seiyaku Kabushiki Kaisha Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6
WO2000010607A1 (fr) * 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Produits preventifs ou therapeutiques de la pancreatite contenant des antagonistes de il-6 comme substance active
WO2002080969A1 (fr) * 2001-04-02 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Remedes pour des maladies liees a l'arthrite chronique du nourrisson
WO2004039826A1 (fr) * 2001-11-14 2004-05-13 Centocor, Inc. Anticorps anti-il-6, compositions, methodes et utilisations associees
WO2005061000A1 (fr) * 2003-12-19 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Remede contre l'angor coronarien

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899902A (ja) * 1994-09-30 1996-04-16 Chugai Pharmaceut Co Ltd Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
JPH08208514A (ja) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分とする慢性関節リウマチ治療剤
JPH10324639A (ja) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
WO1999047170A1 (fr) * 1998-03-17 1999-09-23 Chugai Seiyaku Kabushiki Kaisha Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6
WO2000010607A1 (fr) * 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Produits preventifs ou therapeutiques de la pancreatite contenant des antagonistes de il-6 comme substance active
WO2002080969A1 (fr) * 2001-04-02 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Remedes pour des maladies liees a l'arthrite chronique du nourrisson
WO2004039826A1 (fr) * 2001-11-14 2004-05-13 Centocor, Inc. Anticorps anti-il-6, compositions, methodes et utilisations associees
WO2005061000A1 (fr) * 2003-12-19 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Remede contre l'angor coronarien

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCUDERI F. ET AL.: "IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis", JOURNAL OF NEUROIMMUNOLOGY, vol. 176, July 2006 (2006-07-01), pages 9 - 15, XP025039292, DOI: doi:10.1016/j.jneuroim.2006.03.026 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017677B2 (en) 1997-03-21 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Methods of treating a disease mediated by sensitized T cells
US9255145B2 (en) 2001-04-02 2016-02-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US9051384B2 (en) 2002-02-14 2015-06-09 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US10744201B2 (en) 2003-04-28 2020-08-18 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate
US8709409B2 (en) 2003-04-28 2014-04-29 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
US9902777B2 (en) 2004-03-24 2018-02-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing subtypes of humanized antibody against interleukin-6 receptor
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US8734800B2 (en) 2004-03-24 2014-05-27 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
US11008394B2 (en) 2007-12-27 2021-05-18 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US8568720B2 (en) 2007-12-27 2013-10-29 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US11767363B2 (en) 2007-12-27 2023-09-26 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US11584798B2 (en) 2007-12-27 2023-02-21 Hoffmann-La Roche Inc. High concentration antibody-containing liquid formulation
US11359026B2 (en) 2007-12-27 2022-06-14 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US10501769B2 (en) 2009-10-26 2019-12-10 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11021728B2 (en) 2009-10-26 2021-06-01 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11136610B2 (en) 2009-10-26 2021-10-05 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11377678B2 (en) 2009-10-26 2022-07-05 Hoffman-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US8580264B2 (en) 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
US10874677B2 (en) 2010-11-08 2020-12-29 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US9750752B2 (en) 2010-11-08 2017-09-05 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US10231981B2 (en) 2010-11-08 2019-03-19 Chugai Seiyaku Kabushiki Kaisha Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
US11622969B2 (en) 2010-11-08 2023-04-11 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US11667720B1 (en) 2010-11-08 2023-06-06 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US9539263B2 (en) 2010-11-08 2017-01-10 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
US10761091B2 (en) 2013-07-04 2020-09-01 Hoffmann-La Roche, Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US10168326B2 (en) 2013-07-04 2019-01-01 F. Hoffmann-La Roche Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Also Published As

Publication number Publication date
CL2007003817A1 (es) 2008-06-27
PE20081547A1 (es) 2009-01-18
JP2010095445A (ja) 2010-04-30
AR064538A1 (es) 2009-04-08

Similar Documents

Publication Publication Date Title
WO2008078715A1 (fr) Agent thérapeutique pour une myopathie inflammatoire contenant un antagoniste de il-6 en tant qu'ingrédient actif
WO2008005345A3 (fr) Compositions d'antagonistes de 5-ht3 et d'antagonistes de dopamine d2 pour le traitement d'états chroniques associés à la dopamine
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
IL193444A (en) Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
WO2007119214A3 (fr) Traitement précoce de fibrose pulmonaire idiopathique
EA201200795A1 (ru) Связывающие элементы для пептида с5а с высоким ингибирующим действием
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
WO2009144555A8 (fr) Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2008064321A3 (fr) Procédés de traitement des maladies inflammatoires chroniques à l'aide d'un antagoniste du gm-csf
WO2012059598A3 (fr) Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
WO2006052723A3 (fr) Agonistes et antagonistes de recepteurs couples aux proteines g et methodes d'utilisation
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2007120284A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2008057579A3 (fr) Formes dosifiées et co-administration d'un agoniste opioïde et d'un antagoniste opioïde
IL207440A (en) Use of an antagonist antibody against a related peptide-calcitonin gene (cgrp) in the preparation of a drug for the prevention and / or treatment of chronic pain and / or symptoms of chronic pain and pharmaceutical preparations and kits containing it
WO2007050802A3 (fr) Nouveaux antagonistes opioides
WO2009082038A3 (fr) Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
WO2008128126A8 (fr) Compositions et procédés pour la prophylaxie et le traitement des addictions
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
WO2011004028A3 (fr) Agents de liaison à tlr3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859981

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859981

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP